Table 2.
Current studies describing symptom and disease manifestations in the post-COVID-19 period.
| STUDIES | F/U | F/U Time | n | CP* | Palpitations* | SOB* | Inc HR* | Arrhythmia* | Syncope* | HTN* | CM* | Pericarditis* | Myopericarditis* | Myocarditis* | DD* | PulmHTN* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carfi (42) | F2F | 60d | 143 | 21.7 | - | 43.4 | - | - | - | - | - | - | - | - | - | - |
| Carvahlo (43) | Tele | 30d; 60d |
150 | 18.0 13.1 | 6.5; 10.9 |
10.7; 7.7 | - | - | - | - | - | - | - | - | - | - |
| Garrigues (44) | Tele | 3-4m | 120 | 10.8 | - | 41.7 | - | - | - | - | - | - | - | - | - | - |
| Halpin (45) | Tele | 4-8w | 68h 32I |
- | - | 42.6 65.6 |
- | - | - | - | - | - | - | - | - | - |
| Chopra(46) | Tele | 60d | 488 | - | - | 16.5 | - | - | - | - | - | - | - | - | - | - |
| Fayol(41) | F2F | 6m | 48 | 6 | - | 56 | - | - | - | - | - | - | - | - | 8 | 6.8 |
| Davis (38) | Survey | 1-6m | 3762 | 54.7 | 68.8 | 77.4 | - | 62.9 | 12.9 | - | - | - | - | - | - | - |
| Huang (40) | F2F | 6m | 1733 | 5 | 9 | 23 | - | - | - | - | - | - | - | - | - | - |
| Dennis(47) | Survey | 4w | 201 | 76 | - | 88 | - | - | - | - | 9 | - | - | 19.4** | - | - |
| Xiong(48) | Tele | 3m | 538 | 12.3 | 4.8 | 26.1 | 11.2 | - | - | - | - | - | - | - | - | - |
| Eiros(39) | F2F | 4.4-10.4w | 139 | 19 | 14 | 26 | - | 26 | - | - | 5 | 3 | 11 | 26 | - | - |
| Finn(49) | F2F | 1-11m | 13 | - | - | - | - | - | - | - | 38.4 | - | - | - | - | - |
F2F- face to face; h-hospitalized but not in ICU; I-ICU admission; Tele- telephone survey; w- weeks; d- days; m-months; *All findings are reported as percentages; ** This may be falsely elevated as the study used abnormal T1 on CMR as the sole criteria to diagnose myocarditis.